The Indian pharmaceutical and healthcare sector is anticipated to witness moderate revenue growth of 11% year-on-year for the March quarter, as reported by HDFC Securities. While pharmaceutical companies are expected to achieve 10% YoY sales growth, driven by a 15% increase in the domestic market, this will be countered by a 5% quarter-on-quarter decline in US formulations due to pricing pressures and the absence of high-margin sales from gRevlimid. EBITDA margins are projected to decrease by 110 basis points YoY, influenced by rising input costs and steady research and development expenses. The hospital sector is expected to grow by 15% YoY, supported by stable occupancy rates and increased bed capacity. Additionally, the diagnostics segment is projected to achieve 15% YoY sales growth, while retail pharmacy chains like Medplus and Apollo HealthCo are expected to see growth rates of 22% and 20% YoY, respectively. Overall, the report highlights a mixed performance across various segments, with challenges in the US market affecting overall profitability.